Phorbol Ester Stroke Treatment via NF-kB Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke are inadequate, with high mortality and morbidity rates, and existing pharmaceutical agents like phorbol esters face challenges due to toxicity and limited effectiveness in managing inflammatory reactions associated with stroke.
Innovation Solution
Compositions and methods utilizing phorbol esters and their derivatives, specifically 12-O-tetradecanoylphorbol-13-acetate (TPA), to modulate cell signaling pathways, alter cytokine release, and treat or prevent stroke-related symptoms such as paralysis, memory loss, and cognitive impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phorbol esters are used to activate protein kinase C and modulate cell signaling pathways, then therapeutic effects for stroke treatment are achieved, but toxicity and inflammatory responses worsen
Solution Approach 1:
The patent applies this principle by utilizing the inflammatory and immune-stimulating properties of phorbol esters, which were traditionally considered harmful side effects, as therapeutic mechanisms to treat stroke. The composition leverages the ability of TPA to activate protein kinase C and modulate cell signaling pathways, including NF-κB and MAPK pathways, to achieve neuroprotective effects and improve cognitive function after stroke, converting what was previously viewed as toxicity into a beneficial therapeutic action.
2Reliability
If current pharmaceutical agents are used for stroke treatment, then some therapeutic effects are achieved, but mortality and morbidity rates remain high
Solution Approach 1:
The patent applies this principle by changing the pharmacological parameters of stroke treatment through the use of phorbol ester compositions. Specifically, the invention modifies cell signaling pathway activation parameters, cytokine release profiles, and inflammatory response characteristics to achieve superior therapeutic outcomes. The composition demonstrates improved efficacy in reducing mortality and morbidity rates compared to conventional treatments by targeting multiple pathways including NF-κB modulation and Th1 cytokine activation.
3Reliability
If phorbol esters are used to modulate NF-κB activity and increase Th1 cytokine activity, then stroke sequelae severity is reduced, but concerns about tumor promotion and inflammatory reactions arise
Solution Approach 1:
The patent applies this principle by administering phorbol esters at controlled doses that achieve sufficient modulation of NF-κB activity and Th1 cytokine release to produce therapeutic benefits, while avoiding excessive activation that could lead to harmful inflammatory responses or tumor promotion. The composition is designed to deliver the minimum effective dose required to reduce stroke sequelae severity, including improvements in cognitive function and coordination, while maintaining safety by preventing overactivation of pro-inflammatory pathways.
Data Source
AI summary
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.